Chemotherapy-induced hair loss is widely recognised as one of the most traumatic side effects associated with cancer treatment, and yet it is still one of the least explored. We are changing that.
Paxman has been pioneering scalp cooling technology for over a quarter of a century. Our clinically proven cold cap system has helped over 100,000 cancer patients in more than 25 countries worldwide to retain their hair during chemotherapy.
The use of scalp cooling or ‘cold caps’ is proven to be an effective way of combatting chemotherapy-induced hair loss and can result in a high level of retention or completely preserve the hair. For patients, this means the opportunity to regain some control, maintain their privacy and encourage a positive attitude towards treatment.
Scalp cooling (the cold cap) can be used with all solid tumour cancers that are treated with chemotherapy drugs such as taxanes (e.g. docetaxel), alkylating agents (e.g. cyclophosphamide) and anthracyclines/DNA intercalating agents (e.g. doxorubicin). These drugs target rapidly dividing cells and the matrix keratinocytes, which results in hair loss (Paus et al., 2013).
Scalp cooling cannot be used with the following conditions:
